Page last updated: 2024-10-27

gabexate and Carcinoma in Situ

gabexate has been researched along with Carcinoma in Situ in 1 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.

Research Excerpts

ExcerptRelevanceReference
"Camostate caused an increase in growth of the pancreas and a decrease in the number of (pre)neoplastic ductular pancreatic lesions."1.28Effects of the synthetic trypsin inhibitor camostate on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters. ( Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1991)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Meijers, M1
van Garderen-Hoetmer, A1
Lamers, CB1
Rovati, LC1
Jansen, JB1
Woutersen, RA1

Other Studies

1 other study available for gabexate and Carcinoma in Situ

ArticleYear
Effects of the synthetic trypsin inhibitor camostate on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.
    Cancer letters, 1991, Dec-01, Volume: 60, Issue:3

    Topics: Animals; Carcinogens; Carcinoma; Carcinoma in Situ; Cholecystokinin; Cricetinae; Esters; Gabexate; G

1991